Rituxan Hycela (Genentech, Inc.)
Welcome to the PulseAid listing for the Rituxan Hycela drug offered from Genentech, Inc.. This CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC],Endoglycosidase [EPC],Glycoside Hydrolases [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Genentech, Inc. |
NON-PROPRIETARY NAME: | rituximab and hyaluronidase |
SUBSTANCE NAME: | RITUXIMAB; HYALURONIDASE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC],Endoglycosidase [EPC],Glycoside Hydrolases [Chemical/Ingredient] |
ROUTE: | SUBCUTANEOUS |
DOSAGE FORM: | INJECTION, SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2017-06-22 |
END MARKETING DATE: | 0000-00-00 |
Rituxan Hycela HUMAN PRESCRIPTION DRUG Details:
Item Description | Rituxan Hycela from Genentech, Inc. |
LABELER NAME: | Genentech, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 120; 2000(mg/mL; U/mL) |
START MARKETING DATE: | 2017-06-22 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 50242-108_a0e2f964-625a-4002-b1b5-c8fc6fe3c50a |
PRODUCT NDC: | 50242-108 |
APPLICATION NUMBER: | BLA761064 |
Other RITUXIMAB; HYALURONIDASE Pharmaceutical Manufacturers / Labelers: